186 related articles for article (PubMed ID: 26115122)
21. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
22. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
24. 14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2.
Chen Y; Li Z; Dong Z; Beebe J; Yang K; Fu L; Zhang JT
Mol Cancer Res; 2017 Apr; 15(4):418-428. PubMed ID: 28087741
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
26. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.
Eto K; Iwatsuki M; Watanabe M; Ishimoto T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Int J Cancer; 2015 Apr; 136(7):1537-45. PubMed ID: 25159729
[TBL] [Abstract][Full Text] [Related]
27. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer.
Gong P; Zhang T; He D; Hsieh JT
Radiat Res; 2015 Dec; 184(6):630-8. PubMed ID: 26632856
[TBL] [Abstract][Full Text] [Related]
29. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
30. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
[TBL] [Abstract][Full Text] [Related]
31. miR-708 acts as a tumor suppressor in human glioblastoma cells.
Guo P; Lan J; Ge J; Nie Q; Mao Q; Qiu Y
Oncol Rep; 2013 Aug; 30(2):870-6. PubMed ID: 23754151
[TBL] [Abstract][Full Text] [Related]
32. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
33. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
[TBL] [Abstract][Full Text] [Related]
34. MCL-1 dependency of cisplatin-resistant cancer cells.
Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
[TBL] [Abstract][Full Text] [Related]
35. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
[TBL] [Abstract][Full Text] [Related]
36. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
38. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.
Li Y; Li W; Yang Y; Lu Y; He C; Hu G; Liu H; Chen J; He J; Yu H
Brain Res; 2009 Aug; 1286():13-8. PubMed ID: 19559015
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]